Effect of sulglycotide on the release of PGI 2 into gastric juice in healthy volunteers

A new liquid preparation of sulglycotide, a sulfate glycopeptide with gastro protective properties, has recently been developed. The present study compared the bioequivalence of the new formulation with that of the oral granular preparation in terms of the release of 6-keto prostaglandin F(1α) (PGF(1α)) a stable metabolite of prostaglandin I 2, in human gastric juice. Twenty-four healthy volunteers were randomized to receive either the suspension or the granular preparation for 7 days. At the end of treatment, both sulglycotide formulation had significantly increased the release of 6- keto PGF(1α) into gastric juice. These results demonstrate bioequivalence of the two tested formulations and explain in part the therapeutic effect of sulglycotide in peptic disease.